A whopping 29 out of 163 patients developed PCS (Post-COVID-19 Syndrome). That’s 17.8%. If 1 in 5 people were developing Long COVID after infection, then there would be too much Long COVID relative to what’s actually happening. It’s just too high. So, unfortunately, for that reason, I wouldn’t consider this to be a Long COVID study (the kind of Long COVID that leaves many people unemployed and seeking answers from support groups and other sufferers). What they studied (PCS) is not Long COVID.
- The researchers looked for EBV DNA in blood. They didn’t find anything unusual. They also looked for other signs such as antibodies against EBV and neopterin, a marker for antiviral immune responses.
- SARS-CoV-2 antibody levels were declining in all participants in comparable manner over time, pointing to a successful virus clearance.